EVAXION BIOTECH A/S - CVR: 31762863

2022, DKK

07.06.2023

Bruttoresultat

507'

Primær drift

-153''

Årets resultat

-152''

Aktiver

92.465'

Kortfristede aktiver

56.095'

Egenkapital

-31.893'

Afkastningsgrad

-166 %

Soliditetsgrad

-34 %

Likviditetsgrad

105 %

Resultat

07.06.2023

Årsrapport	2022 07.06.2023	2021 23.05.2022	2020 04.06.2021	2019 18.11.2020	2018 04.04.2019	2017 09.06.2018	2016 02.06.2017	2015 19.06.2016
Nettoomsætning	507.000
Bruttoresultat	507.000	0	0	0	-8.390.221	-4.454.031	-523.547	-5.082.775
Resultat af primær drift	-153.156.000	-180.483.000	-183.407.000	-92.847.000	-21.504.659	-13.162.453	-6.313.465	-8.138.300
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0	0
Finansielle indtægter	6.646.000	19.881.000	9.954.000	1.436.000	479.953	15.798	60.207	202.525
Finansieringsomkostninger	-11.641.000	-10.865.000	-2.824.000	-1.409.000	0	0	0	0
Andre finansielle omkostninger	0	0	0	0	-678.165	-88.016	-19.696	-26.106
Resultat før skat	-157.914.000	-169.792.000	-160.415.000	-103.418.000	-21.702.871	-13.234.671	-6.272.954	-7.961.881
Resultat	-152.414.000	-164.292.000	-154.885.000	-97.918.000	-17.060.437	-10.370.605	-5.022.641	-6.029.250
Forslag til udbytte	0	0	0	0	0	0	0	0

Aktiver

07.06.2023

Årsrapport	2022 07.06.2023	2021 23.05.2022	2020 04.06.2021	2019 18.11.2020	2018 04.04.2019	2017 09.06.2018	2016 02.06.2017	2015 19.06.2016
Kortfristede varebeholdninger	0	0	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	18.529.000	25.452.000	12.967.000	25.306.000	5.402.563	13.367.276	3.060.297	1.971.347
Likvider	37.566.000	85.237.000	209.641.000	34.758.000	48.461.612	2.906.405	7.584.515	11.128.167
Kortfristede aktiver	56.095.000	110.689.000	222.608.000	60.064.000	53.864.175	16.273.681	10.644.812	13.099.514
Immaterielle aktiver og goodwill	0	0	608.000	608.000	0	710.008	887.044	1.157.933
Finansielle anlægsaktiver	7.077.000	7.147.000	5.855.000	8.494.000	120.297	197.097	0	0
Materielle aktiver	29.293.000	32.601.000	33.941.000	1.327.000	130.421	129.281	55.592	0
Langfristede aktiver	36.370.000	39.748.000	40.404.000	10.429.000	250.718	1.036.386	942.636	1.157.933
Aktiver	92.465.000	150.437.000	263.012.000	70.493.000	54.114.893	17.310.067	11.587.448	14.257.447

Aktiver

07.06.2023

Passiver

07.06.2023

Årsrapport	2022 07.06.2023	2021 23.05.2022	2020 04.06.2021	2019 18.11.2020	2018 04.04.2019	2017 09.06.2018	2016 02.06.2017	2015 19.06.2016
Forslag til udbytte	0	0	0	0	0	0	0	0
Egenkapital	-31.893.000	57.888.000	212.818.000	42.615.000	38.414.458	15.841.434	10.048.971	13.018.435
Hensatte forpligtelser	1.007.000	1.007.000	1.007.000	0	0	0	0	0
Langfristet gæld til banker	0	54.827.000	0	0	0	0	0	0
Anden langfristet gæld		0	0	0	0	0	0	0
Leverandører af varer og tjenesteydelser	18.135.000	12.339.000	18.031.000	14.534.000	904.535	368.842	987.620	744.292
Kortfristede forpligtelser	53.303.000	23.104.000	27.859.000	27.878.000	15.700.435	1.468.633	1.538.477	1.239.012
Gældsforpligtelser	123.351.000	92.549.000	50.194.000	27.878.000	15.700.435	1.468.633	1.538.477	1.239.012
Forpligtelser	123.351.000	92.549.000	50.194.000	27.878.000	15.700.435	1.468.633	1.538.477	1.239.012
Passiver	92.465.000	150.437.000	263.012.000	70.493.000	54.114.893	17.310.067	11.587.448	14.257.447

Passiver

07.06.2023

Nøgletal

07.06.2023

Årsrapport	2022 07.06.2023	2021 23.05.2022	2020 04.06.2021	2019 18.11.2020	2018 04.04.2019	2017 09.06.2018	2016 02.06.2017	2015 19.06.2016
Afkastningsgrad	-165,6 %	-120,0 %	-69,7 %	-131,7 %	-39,7 %	-76,0 %	-54,5 %	-57,1 %
Dækningsgrad	100,0 %	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Resultatgrad	-30.061,9 %	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	477,9 %	-283,8 %	-72,8 %	-229,8 %	-44,4 %	-65,5 %	-50,0 %	-46,3 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-1.315,7 %	-1.661,1 %	-6.494,6 %	-6.589,6 %	Na.	Na.	Na.	Na.
Soliditestgrad	-34,5 %	38,5 %	80,9 %	60,5 %	71,0 %	91,5 %	86,7 %	91,3 %
Likviditetsgrad	105,2 %	479,1 %	799,1 %	215,5 %	343,1 %	1.108,1 %	691,9 %	1.057,3 %

Resultat

07.06.2023

Gæld

07.06.2023

Årsrapport

07.06.2023

Nyeste:01.01.2022- 31.12.2022(offentliggjort: 07.06.2023)

Beretning

07.06.2023

Dato for ledelsens godkendelse af årsrapporten:2024-03-27

Ledelsespåtegning:Management's statement

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have approved the annual report of EvaxionBiotech A/S for the financial year 1 January - 31 December 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Primary ActivityWe are a clinical-stage TechBio company that aspires to lead the exploration of artificial intelligence, or AI, to develop vaccines with improved efficacy when compared to currently marketed products for patients with unmet medical needs. We were founded in 2008 as an AI company and over the years have developed into an AI-TechBio company with a robust clinical pipeline of personalized cancer vaccines and a broad pre- clinical pipeline of vaccines for various infectious diseases. Our pipeline programs are derived from our proprietary AI-Immunology™ platform, consisting of several models: PIONEER™, ObsERV™, AI-DeeP™, EDEN™, and RAVEN™ and we are utilizing these unique AI models to build a strong drug development pipeline. Drug development is a long and costly process with high attrition rates. We believe our unique AI-Immunology™ platform, trained to translate vast amounts of data to identify novel targets for the development of unique vaccines, have the potential to significantly reduce drug development timelines, costs and attrition. We aim to capture the value from the predictive power of our proprietary AI-Immunology™ platform and its ability to identify novel targets for drug development by building a solid pipeline of AI-powered vaccines within the areas of cancer and infectious diseases, both attractive markets with high unmet medical needs. The associated business model is to partner our vaccines after pre-clinical or clinical Proof of Concept, or PoC, with large biopharmaceutical and pharmaceutical companies to conduct clinical trials, regulatory and marketing approval and commercialization of our product candidates. We are currently advancing our first two product vaccine candidates, EVX-01 and EVX-02, for the treatment of various solid cancers. Our third cancer vaccine candidate, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is a clinically ready asset. We are actively seeking partnership opportunities to further advance the development of the EVX-03 vaccine candidate. In addition, we are currently developing three pre-clinical bacterial vaccine product candidates, EVX-B1, EVX-B2 and EVX-B3, targeting Staphylococcus aureus, or S. aureus, and Neisseria gonorrhøæ, or N. gonorrhøæ infections, and an undisclosed bacteria target respectively, and one viral vaccine product candidate, EVX-V1, targeting cytomegalovirus, or CMV. Our AI - Immunology (TM) Platform and Product Development PipelineThe immune system is widely regarded as a highly important defense system. We use the power of AI to decode the immune system and to direct it towards internal or external threats such as cancer and infectious diseases. Our AI technologies include the immuno-oncology AI models PIONEER™ & ObsERV™, the bacterial and viral disease AI models EDEN™ & RAVEN™, and our Immune Checkpoint Inhibitor responder AI model AI-DeeP™. These AI technologies are based on the current understanding of the human immune system and can transform large amounts of biological data into algorithms that may accurately predict cellular interactions within the immune system and potentially more accurately identify targets that will stimulate a relevant immune response. We believe that the predictive power of our AI models will reduce both the development time and risk of failure during the various stages of drug development. We have demonstrated that our AI models are able to identify novel targets in just days, rather than years as is common for standard drug discovery methods. We believe that this predictive accuracy can significantly decrease the risk of failure by reducing the risk of low efficacy or unacceptable toxicity. PIONEER™ is our AI model for the discovery of patient-specific cancer targets which we use to develop truly personalized cancer vaccines. PIONEER™ identifies patient-specific tumor mutations, so called neoantigens, that can induce strong T-cell dependent immune responses leading to tumor eradication. We believe such neoantigen-based therapies will induce a directed immune response to each patient’s tumor that can eradicate the cancer cells from the body. We are currently developing three programs for personalized cancer vaccines; EVX-01, EVX-02, and EVX-03, of which the first two are currently in clinical development. ObsERV™ is our AI model for the discovery of patient- or indication-specific virus-derived targets, so- called ERVs (endogenous retroviruses), selectively expressed in cancer. We have demonstrated that overexpression of such ERVs antigens is strongly associated with the overall survival of cancer patients. In addition, we have preclinically demonstrated complete tumor eradication in animal models when targeting ObsERV™ identified ERVs. We believe that ERV-based therapies will induce a directed T-cell dependent immune response leading to tumor eradication. Our EVX-03 vaccine candidate contains a combination of PIONEER™ predicted neoantigens and ObsERV™ predicted ERV antigens. AI-DeeP™ is our AI model for predicting patient responses to cancer checkpoint inhibitor immunotherapy. The AI model can predict patient immunotherapy treatment outcomes with high precision and may inform decision on treatment. AI-DeeP™ is part of the ‘Responder’ leg of our corporate strategy. EDEN™ is our AI model for the discovery of B-cell antigen vaccine targets. EDEN™ has been designed to identify novel infectious disease B-cell antigen targets that, we believe, have the potential to be more effective than what have previously been identified using standard drug discovery methods. We apply EDEN in our current development of three pre-clinical bacterial vaccine programs; EVX-B1, targeting Staphylococcus aureus, or S. aureus infections, EVX-B2/EVX-B2-mRNA targeting Neisseria gonorrhøæ, or N. gonorrhøæ infections, and EVX-B3, targeting an undisclosed bacterial pathogen with a high medical need where no vaccine is currently available. We believe EDEN is applicable for virus vaccine development, hence it is applied in the development of our EVX-V1 virus vaccine against cytomegalovirus (CMV). RAVEN™ is our AI model for the discovery of vaccine antigen targets, that can induce strong T-cell immune responses for infectious diseases. We apply RAVEN in our current development of the pre-clinical viral vaccine program; EVX-V1, targeting cytomegalovirus (CMV). We believe RAVEN is also applicable for bacterial vaccine development, hence it is applied in the development of EVX-B3.